BARWON HEALTH | MedPath

Recce Pharmaceuticals' R327G Shows 93% Efficacy in Phase II Trial for Bacterial Skin Infections

7 months ago

• Recce Pharmaceuticals' R327G topical gel achieved a 93% primary efficacy endpoint in treating acute bacterial skin and skin structure infections (ABSSSI) and diabetic foot infections (DFI). • The Phase II trial demonstrated rapid clinical response, with 86% of patients showing improvement after 7 days and no serious adverse events reported. • Building on these results, Recce plans to advance to Phase III trials in Australia for ABSSSI/DFI and in Indonesia for DFI, aiming for potential commercialization by 2026. • The FDA's emphasis on broad-spectrum antibiotics aligns with R327G's potential to address antimicrobial resistance, offering a promising solution for diverse bacterial infections.

Recce Pharmaceuticals' Phase II Trial of R327G for ABSSSI Reaches Halfway Enrollment

7 months ago

• Recce Pharmaceuticals has dosed 15 patients in its Phase II trial of RECCE® 327 topical gel (R327G) for acute bacterial skin and skin structure infections (ABSSSI). • The open-label, pilot efficacy study is evaluating the efficacy and systemic absorption of R327G when applied directly to infected areas, aiming to enroll 30 participants by year-end. • R327G has demonstrated promising antibacterial effects and has been well-tolerated, suggesting potential for broader application in treating skin infections. • The ABSSSI market is expanding due to increasing bacterial skin infections and drug-resistant strains, highlighting the need for effective broad-spectrum antimicrobials.